Histological analysis of TGFβ1 and VEGFR expression in cervical carcinoma treated with Rhodomyrtus tomentosa

Putri Cahaya Situmorang1, Rostime Hermayerni Simanullang1,2, Rony Abdi Syahputra3, Masta Melati Hutahaean2, Hizkianta Sembiring2, Lailatun Nisfa1, Endang Ratna Sari1

1 Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia
2 Sekolah Tinggi Ilmu Kesehatan Murni Teguh, Medan, Indonesia
3 Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia

Corresponding author: Putri Cahaya Situmorang (putri.cahaya@usu.ac.id)

Received 28 October 2022  ♦  Accepted 17 January 2023  ♦  Published 15 March 2023


Abstract
Cervical carcinoma is one of the most common malignant carcinomas around the world, including Indonesia. Rhodomyrtus tomentosa is an herbal medicine that is often used in Asia as a therapeutic agent to stop cancer metastases. The process of neoangiogenesis in cervical cancer depends on VEGFR activity. Increased TGFβ1 production is also linked to cervical cancer, suggesting that gene inactivation contributes to the emergence of cervical carcinoma.

Group C- was the control group, Group C+ was the cancer model group, CER100 was the group of rats with cancer + 100 mg/kg body weight (BW) of R. tomentosa, CER200 was the group of rats with cancer + 200 mg/kg BW of R. tomentosa, and CER400 was the group of rats with cancer + 400 mg/kg BW R. tomentosa. Rats were dissected after administration of R. tomentosa for 30 days.

Immunohistochemical staining of the cervical tissue was performed with TGFβ1 and VEGFR antibodies. VEGFR expression was significantly different from TGFβ1 expression (p < 0.01). The highest expression was observed at the lowest dose of R. tomentosa (100 mg/kg BW), and the lowest expression was observed at 200 and 400 mg/kg BW. The administration of R. tomentosa can repair tissue damage and decrease the expression of TGFβ1 and VEGFR via histopathological parameters, indicating the importance of the activity of these proteins in the development of neoangiogenesis in cervical cancer.

Keywords
cervical cancer, immunohistochemistry, molecular therapy, Rhodomyrtus tomentosa, TGFβ1, VEGFR

Introduction
Cervical carcinoma of the uterus is one of the most prevalent malignant carcinomas that endangers the lives of women (Conesa-Zamora 2013). Cervical carcinoma accounts for one-half of all malignant tumours that develop in the female reproductive system (Conesa-Zamora 2013). Molecular therapy can be used to cure cancer while using natural herbs (Yin et al. 2013). In cancer treatments, including chemotherapy, certain herbs help to minimise side effects (Yin et al. 2013). Herbs are typically boiled in water to create plant extracts. Rhodomyrtus tomentosa is one of the herbal remedies that is frequently employed by the Asian population (Yin et al. 2013). The ornamen-
Transforming growth factor β1 (TGFβ1) can boost normal cervical remodelling and inhibit cervical cell growth induced by human papillomavirus (HPV) (Wang et al. 2021). HPV infection affects TGFβ signalling (Wang et al. 2021). The presence of TGFβ1 in human cervical cancer suggests that gene inactivation contributes to the emergence of cervical carcinoma. Increased TGFβ1 production or inhibition, mutation of the TGF-transmembrane receptor, or lack of expression and/or mutation of Smads are all linked to cervical cancer (Taylor et al. 2011; Principe et al. 2014). Immune cells of varying types and numbers can be detected in nests of tumour cells that are surrounded by varying densities of intratumoral stroma in cervical cancer (Principe et al. 2014). Transforming growth factor-1 (TGF-1) regulates epithelial cell proliferation and the development of the stroma and extracellular matrix (ECM) and suppresses the immune system (Taylor et al. 2011). Increased TGFβ1 synthesis or changes in intracellular and post-receptor signalling pathways have been linked to several cancers (Taylor et al. 2011). Therapeutic strategies should be designed to prevent the invasive phenotype induced by TGFβ1 while preserving its growth-inhibiting effects and inducing its apoptosis (Taylor et al. 2011; Principe et al. 2014).

The findings of a study on VEGFR1 and TGFβ1 expression highlight the potential of R. tomentosa as a molecular therapy for cancer and provide strong support for its therapeutic use in modern medicine. The effect of R. tomentosa on VEGFR1 and TGFβ1 expression in rat cervical histopathology should be investigated before employing human cells. To increase cell penetration and bioavailability, R. tomentosa was formulated into a micro-colloidal form. It is intended to use this plant to produce drugs for human molecular cancer therapy.

**Materials and methods**

**Materials**

*R. tomentosa* leaves were discovered in the Lintong Nihuta, North Sumatera, Indonesia. The plants were found in the Lintong Nihuta sub-district of Humbahas Regency at elevations ranging from 1,000 to 1,500 m above sea level and located at 02°4’20”–2°16’15”N and 98°52’40”–98°56’20”E. Lintong Nihuta District has 479 ha of peatland, accounting for 16.03% of the total peatland area in Humbang Hasundutan Regency (Hutagaol et al. 2021).

**Preparation of Rhodomyrtus tomentosa**

Preparation: The leaves and twigs of *R. tomentosa* were separated. The leaves were cleansed of any soil or dust that adhered to them, and they were dried for 7 days at room temperature and smoothed.

Extraction: 500 grams of *R. tomentosa* dry powder were macerated in 96% technical ethanol for 24 hours at room temperature. Maceration with a 96% technical ethanol solvent yielded the ethanol extract of *R. tomentosa*. The maceration products were filtered using a Buchner funnel and a vacuum pump. Using the same method, the filtered residue was macerated twice more. A rotary evaporator was used to concentrate the ethanol extract, which was then dried for 8 hours to produce a solid ethanol extract.

Production of micro-colloidal *R. tomentosa* (CER): An ethanol extract of the leaves was prepared by sonication as follows: 0.5 mg of *R. tomentosa* extract was added to a Tween 20 solution. Capryol 90 was added, and the solution was homogenised. PEG-400 was added, and the solution was sonicated. The prepared substance was dissolved in distilled water (1:100) and sonicated with an ultrasonic device (Sonicator Ultrasonic Homogenizers and Emulsifiers), and the micro-colloidal *R. tomentosa* was ready for use in animals experiments.

**Materials and methods**

**Materials**

*R. tomentosa* plants can be harvested in the Lintong Nihuta, North Sumatera, Indonesia. The plants were found in the Lintong Nihuta sub-district of Humbahas Regency at elevations ranging from 1,000 to 1,500 m above sea level and located at 02°4’20”–2°16’15”N and 98°52’40”–98°56’20”E. Lintong Nihuta District has 479 ha of peatland, accounting for 16.03% of the total peatland area in Humbang Hasundutan Regency (Hutagaol et al. 2021).

**Preparation of Rhodomyrtus tomentosa**

Preparation: The leaves and twigs of *R. tomentosa* were separated. The leaves were cleansed of any soil or dust that adhered to them, and they were dried for 7 days at room temperature and smoothed.

Extraction: 500 grams of *R. tomentosa* dry powder were macerated in 96% technical ethanol for 24 hours at room temperature. Maceration with a 96% technical ethanol solvent yielded the ethanol extract of *R. tomentosa*. The maceration products were filtered using a Buchner funnel and a vacuum pump. Using the same method, the filtered residue was macerated twice more. A rotary evaporator was used to concentrate the ethanol extract, which was then dried for 8 hours to produce a solid ethanol extract.

Production of micro-colloidal *R. tomentosa* (CER): An ethanol extract of the leaves was prepared by sonication as follows: 0.5 mg of *R. tomentosa* extract was added to a Tween 20 solution. Capryol 90 was added, and the solution was homogenised. PEG-400 was added, and the solution was sonicated. The prepared substance was dissolved in distilled water (1:100) and sonicated with an ultrasonic device (Sonicator Ultrasonic Homogenizers and Emulsifiers), and the micro-colloidal *R. tomentosa* was ready for use in animals experiments.
**Experimental animals**

This study was conducted at the University of Sumatera Utara’s (USU) Biology, Pathology and Anatomy Laboratory of the Faculty of Medicine from January 2022 to August 2022. The study was conducted using a completely randomised design. This type of research is known as an experimental study. There were five groups: Group C was the control group, Group C+ was the cancer model group, Group CER100 was the group of rats with cancer + 100 mg/kg body weight (BW) of *R. tomentosa*, Group CER200 was the group of rats with cancer + 200 mg/kg BW of *R. tomentosa*, and CER400 was the group of rats with cancer + 400 mg/kg BW *R. tomentosa*. *R. tomentosa* leaf ethanol extract was administered for 30 days orally. The animals were euthanized with administering an anaesthetic combination of 300 mg/kg BW of ketamine and 15–30 mg/kg BW of xylazine was administered then rats were dissected for taken the cervix and cervical tissues were stained with VEGFR1 and TGFβ1 antibodies using immunohistochemical techniques.

**Rat model of cervical cancer**

Thirty female *Rattus norvegicus* were used in this study. The rats were aged 10–15 weeks and weighed 180–200 g. Before being kept in cages at constant room temperature (25.0 ± 3.0 °C) and a humidity level of 35–60%, male rats were introduced to the laboratory environment for 2 weeks. The cages were lit for 12 hours and darkened for 12 hours. Female rats were given unrestricted access to water and free access to corn and pellets. Rats were placed in a plastic container measuring 40 cm × 30 cm. The rats were injected vaginally with 50 mg of benzopyrene diluted with corn oil. The tumour was identified when a lump was found due to administration of benzopyrene for three months. The rats were then administered 

**Measurement of superoxide dismutase**

Superoxide dismutase (SOD) analysis was performed using the blood of the rats with cervical cancer. The Superoxide Dismutase Activity Kit was used to measure SOD activity. After dilution with a uniquely coloured sample diluent, the sample is loaded into wells. Xanthine oxidase reagent was added after the substrate, and the mixture was allowed to sit at room temperature for 20 minutes. In the presence of oxygen, xanthine oxidase generates superoxide, which converts the colourless substrate in the detection reagent to a yellow product that is detectable at 450 nm.

**Measurement of malondialdehyde**

Blood plasma samples from the rats were assessed with traditional thiobarbituric reactive species spectrophotometry (TBARS). The Malondialdehyde (MDA) Assay Kit (competitive enzyme-linked immunosorbent assay) (ab238537) was used for rapid detection and quantification of the protein MDA. This kit enables the quantification of MDA addition in a determined protein sample by comparing its absorbance with a known MDA-BSA standard curve. Then, the MDA-TBA2 condensation product can be measured via UV-VIS spectrophotometry.

**Making paraffin blocks**

Cervical organs were fixed in formalin and immersed in xylol for 15 minutes. After 5 minutes of alternating immersion in 96% and 70% pure alcohol, the tissues were washed with distilled water. After exposure to haematoxylin dye for 5 minutes, the tissues were washed in distilled water for 3 minutes, and the eosin stain was applied for 1 minute. Prior to immersion in xylol, the slides were dried in 70%, 96%, and 100% alcohol. Light microscopy analysis was then performed (Economou et al. 2014).

**Immunohistochemistry**

The histological changes in TGFβ1 and VEGFR expression in cervical carcinoma were investigated using immunohistochemistry after *R. tomentosa* leaf extract administration. The paraffin-fixed cervix samples were deparaffinised and treated for 30 minutes with 1% H2O2 in methanol to decrease endogenous peroxidase activity. The slides were then washed with 0.01 M Tris-buffered saline (pH 7.4). The tissue slices were treated with TGF-1 monoclonal antibody (catalogue #MA1-169 [B11-4C3]), VEGFR1 (soluble) polyclonal antibody (catalogue #36-1100), and Antigen Affinity-Purified Polyclonal Antibody (eBioscience Inc, San Diego, USA). The VECTASTAIN Elite ABC Kit (Vector Laboratories, USA) was used to detect immunoreactivity, which Mayer’s haematoxylin neutralised (McCluggage 2007).

**Data analysis**

The Kruskal–Wallis and Mann–Whitney tests were performed on categorical (ordinal) or numerical data that were not normally distributed after data collection.

**Results**

**Analysis of superoxide dismutase expression in rats with cervical carcinoma treated with Rhodomyrtus tomentosa**

There was a significant difference in SOD levels between the C- and C+ groups based on ANOVA analysis with
Bonferroni post hoc test (p < 0.05) (Table 1). There was no statistically significant difference in SOD level when R. tomentosa was administered for cervical cancer at the lowest dose (100 mg/kg BW) (p > 0.05). However, substantial differences in SOD levels were observed with doses of 200 and 400 mg/kg BW (p < 0.05). Therefore, rats with cervical cancer had increased levels of SOD in their blood when given higher doses of R. tomentosa.

Table 1. Value of Superoxide dismutase by Rhodomyrtus tomentosa in carcinoma cervical.

<table>
<thead>
<tr>
<th>No</th>
<th>Groups</th>
<th>Mean ± SD (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>C-</td>
<td>20.21 ± 3.13</td>
</tr>
<tr>
<td>2</td>
<td>C+</td>
<td>13.01 ± 2.19**</td>
</tr>
<tr>
<td>3</td>
<td>CER100</td>
<td>15.91 ± 2.01</td>
</tr>
<tr>
<td>4</td>
<td>CER200</td>
<td>17.22 ± 1.90*</td>
</tr>
<tr>
<td>5</td>
<td>CER400</td>
<td>19.04 ± 1.23*</td>
</tr>
</tbody>
</table>

C-: Control, C+: Cervical cancer, CER100: Cervical cancer +100 mg/BW of Rhodomyrtus tomentosa, CER200: Cervical cancer + 200 mg/BW of Rhodomyrtus tomentosa, CER400: Cervical cancer + 400 mg/BW of Rhodomyrtus tomentosa. (**p < 0.01 versus C-, *p < 0.05 versus C+).

Analysis of malondialdehyde expression in rats with cervical carcinoma treated with Rhodomyrtus tomentosa

There was a significant difference in MDA level between the C- and C+ groups based on ANOVA analysis with Bonferroni post hoc test (p < 0.05) (Table 2). There was no statistically significant difference in MDA level when R. tomentosa was administered for cervical cancer at the lowest dose (100 mg/kg BW) (p > 0.05). However, significant differences in MDA levels were observed with doses of 200 and 400 mg/kg BW (p < 0.05). Therefore, MDA levels in the blood of rats with cervical cancer decreased with higher doses of R. tomentosa.

Table 2. Value of Malondialdehyde by Rhodomyrtus tomentosa in carcinoma cervical.

<table>
<thead>
<tr>
<th>No</th>
<th>Groups</th>
<th>Mean ± SD (μM/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>C-</td>
<td>7.25 ± 2.01</td>
</tr>
<tr>
<td>2</td>
<td>C+</td>
<td>12.09 ± 3.22*</td>
</tr>
<tr>
<td>3</td>
<td>CER100</td>
<td>9.24 ± 1.09</td>
</tr>
<tr>
<td>4</td>
<td>CER200</td>
<td>8.47 ± 1.11*</td>
</tr>
<tr>
<td>5</td>
<td>CER400</td>
<td>8.12 ± 2.10*</td>
</tr>
</tbody>
</table>

C-: Control, C+: Cervical cancer, CER100: Cervical cancer +100 mg/BW of Rhodomyrtus tomentosa, CER200: Cervical cancer + 200 mg/BW of Rhodomyrtus tomentosa, CER400: Cervical cancer + 400 mg/BW of Rhodomyrtus tomentosa. (**p < 0.01 versus C-, *p < 0.05 versus C+).

Analysis of TGFβ1 expression in rats with cervical carcinoma treated with Rhodomyrtus tomentosa

According to the Kruskal–Wallis test, there was a significant difference (p = 0.000) (Table 3). The expression of TGFβ1 was significantly different from C- based on the average value (p < 0.01). The lowest dose of R. tomentosa (100 mg/kg BW) did not produce a significant change in TGFβ1 expression (p > 0.05); however, doses of 200 and 400 mg/kg BW significantly altered TGFβ1 expression (p < 0.01 and p < 0.05, respectively). TGFβ1 expression was highest in the C+ and CER100 groups, and it was lowest in the CER400 group.

Table 3. Analysis of TGFβ1 expression in carcinoma cervical.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean ± SD</th>
<th>Kruskal-Wallis</th>
<th>Mann-Whitney (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-</td>
<td>10.92 ± 1.02</td>
<td>0.000</td>
<td>0.0001</td>
</tr>
<tr>
<td>C+</td>
<td>72.10 ± 8.22**</td>
<td>0.030</td>
<td>0.010</td>
</tr>
<tr>
<td>CER100</td>
<td>49.09 ± 4.09*</td>
<td>0.040</td>
<td>0.010</td>
</tr>
<tr>
<td>CER200</td>
<td>24.67 ± 4.81***</td>
<td>0.030</td>
<td></td>
</tr>
<tr>
<td>CER400</td>
<td>19.07 ± 3.92**</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C-: Control, C+: Cervical cancer, CER100: Cervical cancer +100 mg/BW of Rhodomyrtus tomentosa, CER200: Cervical cancer + 200 mg/BW of Rhodomyrtus tomentosa, CER400: Cervical cancer + 400 mg/BW of Rhodomyrtus tomentosa. (**p < 0.01 versus C-, *p < 0.05 versus C+, *p < 0.01 Versus C+).

The cervical cells in group C- had histologically normal epithelial lining and nuclei (Fig. 1a). Undifferentiated cells that could develop apoptotic characteristics were restricted to the lowest layer of the epithelium in the rats administered a 50-mg injection of benzopyrene (Fig. 1b). Changes in epithelial cells included thickening of the epithelium and increased TGFβ1 expression. As the dose of R. tomentosa increased (from 100 to 400 mg/kg BW), TGFβ1 expression in the tumour tissue decreased. Using immunohistochemical labelling, R. tomentosa was administered at various doses to decrease the quantity of brown-stained nuclei, which revealed a positive index of TGFβ1 expression in cancer tissues (Fig. 1c–e). The previously uncontrolled growth of carcinomas in the untreated group was effectively slowed down and stopped in the epithelium.

Analysis of VEGFR expression in rats with carcinoma cervical treated with Rhodomyrtus tomentosa

According to the Kruskal–Wallis test, there was a significant difference (p = 0.000) (Table 4). The expression of VEGFR was significantly different from C- based on the average value (p < 0.01). The lowest dose of R. tomentosa (100 mg/kg BW) did not produce a significant change in VEGFR expression (p > 0.05); however, doses of 200 and 400 mg/kg BW significantly altered VEGFR expression (p < 0.01 and p < 0.05, respectively). VEGFR expression was highest in the C+ and CER100 groups, and it was lowest in the CER400 group.

Table 4. Analysis of VEGFR expression in carcinoma cervical.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mean ± SD</th>
<th>Kruskal-Wallis</th>
<th>Mann-Whitney (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-</td>
<td>5.18 ± 4.71</td>
<td>0.000</td>
<td>0.001</td>
</tr>
<tr>
<td>C+</td>
<td>83.88 ± 6.55**</td>
<td>0.070</td>
<td>0.040</td>
</tr>
<tr>
<td>CER100</td>
<td>70.22 ± 7.29**</td>
<td>0.040</td>
<td>0.040</td>
</tr>
<tr>
<td>CER200</td>
<td>25.07 ± 7.09*</td>
<td>0.040</td>
<td></td>
</tr>
<tr>
<td>CER400</td>
<td>19.92 ± 4.02**</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C-: Control, C+: Cervical cancer, CER100: Cervical cancer +100 mg/BW of Rhodomyrtus tomentosa, CER200: Cervical cancer + 200 mg/BW of Rhodomyrtus tomentosa, CER400: Cervical cancer + 400 mg/BW of Rhodomyrtus tomentosa. (**p < 0.05 versus C-, *p < 0.05 versus C+, *p < 0.01 Versus C+).

Normal histological changes are shown in Fig. 2a; however, Fig. 2b shows a carcinoma with an uneven core that migrated to the pelvic wall. R. tomentosa produced a similar histological profile as the C+ group that received a dose.
Figure 1. TGFβ1 expression of Cervical cancer after given *Rhodomyrtus tomentosa*, a. Control (C-); b. Cervical cancer (C+); c. Cervical cancer +100 mg/BW of *Rhodomyrtus tomentosa* (CER100); d. Cervical cancer + 200 mg/BW of *Rhodomyrtus tomentosa* (CER200); e. Cervical cancer + 400 mg/BW of *Rhodomyrtus tomentosa* (CER400). Red arrows: Positive expression. MF: Mucous folds, FLE: Flattened layered epithelium, ICT: Interstitial connective tissue (40X).

Figure 2. VEGFR expression of Cervical cancer after given *Rhodomyrtus tomentosa*, a. Control (C-); b. Cervical cancer (C+); c. Cervical cancer +100 mg/BW of *Rhodomyrtus tomentosa* (CER100); d. Cervical cancer + 200 mg/BW of *Rhodomyrtus tomentosa* (CER200); e. Cervical cancer + 400 mg/BW of *Rhodomyrtus tomentosa* (CER400). Red arrows: Positive expression. MF: Mucous folds, FLE: Flattened layered epithelium, ICT: Interstitial connective tissue (40X).
of 100 mg/kg BW, including large lesions. VEGFR expression at a dose of 200 mg/kg BW (Fig. 2d) revealed that the herb could drastically decrease VEGFR expression; at the maximum dose, cervical cancer stopped developing and the nucleus started to form normally (Fig. 2e).

**Discussion**

Increased MDA and decreased SOD levels were observed in rates with cervical cancer (Tables 1, 2). These two indicators are closely related. The administration of *R. tomentosa* leaf extract balanced SOD and MDA levels. Higher doses of *R. tomentosa* were associated with higher SOD levels and lower MDA levels.

*R. tomentosa*, when administered in various doses, may decrease the prevalence of brown-stained nuclei, which are indicative of TGFβ1 expression in cancer tissue. The growth of the previously uncontrollable malignancy in the untreated group was slowed down and stopped in the epithelium. Immune cells of varying types and numbers can be detected in nests of tumour cells that are surrounded by different densities of intratumoral stroma in cervical cancer (Principe et al. 2014). TGFβ1 production is prevalent in women with cervical cancer (Principe et al. 2014; Taylor et al. 2021). TGFβ1 in cervical cancer reveals that gene inactivation contributes to cervical carcinoma development (Wang et al. 2021). TGFβ1 expression was shown to decrease as the dose of *R. tomentosa* was increased. In addition to being a novel therapeutic drug that reduces cancer metastasis, induces cell cycle arrest, and increases death in gastric carcinoma (Tayeh et al. 2017; Zhang et al. 2020), rhodomyrtone, found in *R. tomentosa*, has been demonstrated to decrease cell migration, adhesion, and invasion of A431 cells (Tayeh et al. 2017; Zhang et al. 2020). The antioxidant significantly inhibited cancer metastases at subcytotoxic concentrations (0.5 and 1.5 g/ml) by decreasing A431 cell motility, cell adhesiveness, and cell invasion, with dose-dependent outcomes (Tayeh et al. 2017). The phosphorylation of a number of proteins, including protein kinase B (AKT), c-Raf, extracellular signal-regulated kinase 1/2 (ERK1/2), and p38 MAPK, which are involved in the downregulation of enzyme activity and the formation of matrix proteins, can also be prevented by rhodomyrtone. Matrix metalloproteinase 9 (MMP-9) and MMP-2 (Tayeh et al. 2017; Luo et al. 2021). Rhodomyrtone, a novel antimetastatic medication for the treatment of cancer cells, inhibits the production and phosphorylation of NF-κB in a dose-dependent manner (Xia et al. 2021). Previous studies have analysed the content of *R. tomentosa*, which contains high levels of antioxidants in nano- or micro-colloid sizes and has low toxicity (Situmorang et al. 2021; Simanullang et al. 2022a).

Cervical cancer development was halted at doses of 200 mg/kg BW to 400 mg/kg BW, indicating that this herb might be effective in suppressing VEGFR expression. An increase in VEGF expression in precancerous changes and cervical cancer is indicative of the role of this proangiogenic factor in the mechanism of neoangiogenesis (Tomao et al. 2014). The discovery of VEGF expression in tissues with poor histopathological characteristics highlights the significance of VEGF activity in the neoangiogenesis and progression of cervical cancer (Sulzmaier and Ramos 2013). VEGFR is sometimes referred to as a chemical that inhibits a blood vessel-forming enzyme (Sulzmaier and Ramos 2013); it is known as an inhibitor of the tyrosine kinase receptor for VEGF. One of the main therapeutic targets in the anti-angiogenic treatment of many malignancies is the VEGFR pathway (Shibuya et al. 2011; Rahmani et al. 2018). VEGFR is an endothelial mitogen that stimulates angiogenesis under both pathological and physiological conditions (Li et al. 2016). Because research on VEGF has gained popularity, it is possible that it serves purposes other than just promoting angiogenesis and vascular permeability (Li et al. 2016; Rahmani et al. 2018). Depending on the specific clinical condition, VEGF can interact with macrophages and T lymphocytes and produce abnormalities in the functional maturation of dendritic cells (Zhao et al. 2022). Furthermore, VEGF signalling, both autocrine and paracrine, supports cancer stem cells. Because *R. tomentosa* has been discovered to exhibit antioxidant, antibacterial, anti-inflammatory, and anticancer properties due to its biological action (Vo and Ngo 2019), increasing the dose of the herb decreases VEGFR expression. Rhodomyrtone, which is present in this herb, can enhance apoptotic bodies, nuclear fragmentation, and chromatin condensation (Tayeh et al. 2017). Rhodomyrtone can be employed as an anticancer treatment because it produces cell cycle arrest in the G1 phase according to flow cytometry studies (Tayeh et al. 2017). Antioxidants have been shown to reduce toxic side effects during cancer treatment (Situmorang et al. 2021). Antioxidant-containing plants, such as *R. tomentosa*, have been associated with cancer treatment with few side effects.

**Conclusion**

The elevated expression of TGFβ1 and VEGFR in cervical carcinoma cells with poor histological characteristics shows how important these proteins’ actions are in the neoangiogenesis and progression of cervical cancer. *R. tomentosa* has been demonstrated to heal carcinogenic metastatic carcinoma tissue; it can be administered at various doses to decrease the number of brown nuclei that exhibit a positive index of TGFβ1 and VEGFR expression in cancer tissues.

**References**


